BioNTech SE (BNTX)
Nasdaq · Healthcare · Biotechnology
$97.64+0.76%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $24.5B
- 52-week range
- $79.52 – $124.00
- 52-week change
- −8.64%
- EPS (trailing)
- −$7.83
- Analyst rating
- 1.7 Buy
- Next earnings
- Nov 3, 2026
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer.
Headquarters: Mainz, Germany · 7,807 employees · biontech.de